TLSI

TriSalus Life Sciences (TLSI)

TriSalus Life Sciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TLSI

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/24	19 : 05	Business Wire	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/15	21 : 00	Business Wire	TriSalus Reports Q1 2024 Financial Results and Business Update	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/07	20 : 00	Business Wire	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/07	05 : 58	Business Wire	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/01	05 : 35	Business Wire	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/04/01	21 : 00	Business Wire	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/26	21 : 00	Business Wire	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/21	21 : 00	Business Wire	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/12	06 : 15	Business Wire	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/07	21 : 00	Business Wire	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/29	21 : 00	Business Wire	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08 : 42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07 : 23	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07 : 21	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/06	06 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	07 : 28	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	07 : 27	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/14	22 : 00	Business Wire	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/08	06 : 05	Business Wire	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/05	03 : 25	Business Wire	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/04	01 : 00	Business Wire	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/10/25	22 : 05	Business Wire	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc